HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women

被引:17
作者
Aman, Nguiessan Alphonse [1 ]
Doukoure, Brahima [2 ]
Koffi, Kouadio Donatien [1 ]
Koui, Baumaney Sylvanus [2 ]
Traore, Zie Cheick [1 ]
Kouyate, Mohamed [2 ]
Effi, Ahoua Benjamin [1 ]
机构
[1] Alassane Ouattara Univ, Sch Med, Dept Anat Pathol, BP V 18 Bouake, Bouake, Cote Ivoire
[2] Felix H Boigny Univ, Sch Med, Dept Anat Pathol, 01 BP V 34 Abidjan 01, Abidjan, Cote Ivoire
关键词
Breast cancer; Estrogen receptor; Human epidermal growth factor receptor 2; Progesterone receptor; IN-SITU HYBRIDIZATION; AMERICAN SOCIETY; EXPRESSION; HER-2/NEU; RECEPTOR; IMMUNOHISTOCHEMISTRY; THERAPY; GENE; RECOMMENDATIONS; BIOMARKERS;
D O I
10.1186/s12907-018-0081-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The overexpression of HER2 is associated with worse prognosis of breast cancer which responds favourably to anti-HER2 therapy. The objective of this study was to determine the frequency of HER2 and its association with clinicopathologic factors in breast cancer in Ivory Coast. Methods: The study included 608 patients who were histologically diagnosed with invasive primary breast carcinoma. The immunohistochemistry testing for ER, PR, and HER2 was performed on the formalin fixed paraffin-embedded blocks of breast tissue of these patients. The analysis of variance and the Chi-Square Test were used to examine the association of the HER2 status with clinicopathologic prognostic features. Results: The average age of patients was 47 +/- 11 years. Among 608 patients, 355 (58.4%) were premenopausal. Invasive ductal carcinoma of no specific type (511 cases, 84.1%) was the most frequent histologic type. Grade II tumors were 59.8%. The positivity of ER, PR, and ER/PR was 334 cases (54.9%), 252 cases (41.4%), and 356 cases (58.5%), respectively. HER2 was overexpressed in 105 cases (17.3%). The overexpression of HER2 was significantly correlated with Nottingham grade (p = 0.007). No association was observed between HER2 expression and age (p = 0.568), menopausal status (p = 0.929), histologic type (p = 0.666), ER (p = 0.137), PR (p = 0.396), and ER/PR (p = 0.134). Conclusion: Breast cancer occurs in young women. HER2 status is closely related to Nottingham grade. The immunohistochemical analysis of HER2 has prognostic and therapeutic implications, and thus, contributing to efficient clinical management of patients.
引用
收藏
页数:6
相关论文
共 46 条
[1]  
Al-Ahwal Mahmoud S., 2006, JPMA Journal of the Pakistan Medical Association, V56, P65
[2]  
[Anonymous], J CLIN ONCOL
[3]  
[Anonymous], 2014, CANC ONCOL RES
[4]   Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma [J].
Ayadi, Lobna ;
Khabir, Abdelmajid ;
Amouri, Habib ;
Karray, Sondes ;
Dammak, Abdallah ;
Guermazi, Mohamed ;
Boudawara, Tahya .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2008, 6 (1)
[5]  
Balcerczak E, 2003, J EXP CLIN CANC RES, V22, P247
[6]   Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer [J].
Bauer, Katrina ;
Parise, Carol ;
Caggiano, Vincent .
BMC CANCER, 2010, 10
[7]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[8]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[9]   Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials [J].
Dahabreh, Issa J. ;
Linardou, Helen ;
Siannis, Fotios ;
Fountzilas, George ;
Murray, Samuel .
ONCOLOGIST, 2008, 13 (06) :620-630
[10]   Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer [J].
Dowsett, Mitch ;
Dunbier, Anita K. .
CLINICAL CANCER RESEARCH, 2008, 14 (24) :8019-8026